הרשות האירופאית לבטיחות במזון ממליצה ומאשרת כי DHA מסייע לתפקוד תקין של המוח ומערכת הראייה

SCIENTIFIC OPINION

Scientific Opinion on the substantiation of health claims related todocosahexaenoic acid (DHA) and maintenance of normal (fasting) blood concentrations of triglycerides (ID 533, 691, 3150), protection of blood lipids from oxidative damage (ID 630), contribution to the maintenance orachievement of a normal body weight (ID 629), brain, eye and nerve development (ID 627, 689, 704, 742, 3148, 3151), maintenance of normal brain function (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151), maintenance of normal vision (ID 627, 632, 743, 3149) and maintenance of normal spermatozoa motility (ID 628) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 1

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

 

Brain, eye and nerve development

The claimed effects are “brain, eye and nerve development”, “optimisation of brain maturation”, “human neurodevelopment”, “brain health and function”, “brain development and function”,  and “maternal health”.

Brain, eye and nerve development is interpreted by the Panel as children‟s  development. The Panel notes that claims related to children's development and health are outside the scope of Article 13 of  Regulation (EC) No 1924/2006.

Maintenance of normal brain function

The claimed effects are “mental state and performance”, “DHA plays an important role in cognitive functions at any stage of life”, “brain health and function”, “optimisation of brain maturation”, “brain development and function”, “human neurodevelopment”, “maternal health” and “cognitive function in the elderly”.  The target population is assumed to be the general population. In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effect refers to the maintenance of normal brain function. The Panel considers that maintenance of normal brain function is a beneficial physiological effect.

The Panel notes that there is a well established role of DHA in brain function.

The Panel concludes that a cause and effect relationship has been established between the consumption of DHA and the maintenance of normal brain function.

The Panel considers that in order to bear the claim, foods should contain 250 mg of DHA in one or more servings. Such amounts can be consumed as part of a balanced diet. The target population is the general population.

Maintenance of normal vision

The claimed effects are “brain, eye and nerve development”, “visual health and function”, and “eye health”. The target population is assumed to be the general population. In the context of the proposed wordings and clarifications provided by Member States, the Panel  assumes that the claimed effect refers to the maintenance of normal vision. The Panel considers that maintenance of normal vision is a beneficial physiological effect.

The Panel notes that there is a well established role of DHA in retinal function.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the consumption of DHA and the maintenance of normal vision.

The Panel considers that in order to bear the claim, foods should contain 250 mg of DHA in one or more servings. Such amounts can be consumed as part of a balanced diet. The target population is the general population.

Maintenance of normal (fasting) blood concentrations of triglycerides

The claimed effect is “heart health”. The target population is assumed to be the general population. In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that  the claimed effect  refers to the maintenance of normal blood concentrations of triglycerides. The Panel considers that  maintenance of normal  (fasting)  blood concentrations of triglycerides may be a beneficial physiological effect.

Among the references provided, two systematic reviews specifically addressed the effects of DHA alone on blood concentrations of triglycerides. Both reviews reported on randomised clinical trials (RCTs) in humans showing statistically significant reductions in triglyceride concentrations after DHA supplementation at daily doses of 3-4 g, whereas no significant changes were observed at daily doses <2 g per day.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has been established between the  consumption of DHA and the maintenance of normal (fasting) blood concentrations of triglycerides.

In order to obtain the claimed effect, 2 g per  day of DHA should be consumed in one or more servings. The target population is adult men and women.